An interventional study of tACS (aperiodic) in Antenatal Depression, Major Depressive Disorder and Major Depressive Disorder in Pregnancy, sponsored by University of North Carolina, Chapel Hill. Terminated at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by University of North Carolina, Chapel Hill · Not applicable, Interventional, and Other
Due to lack of resources the study was terminated.
The purpose of this study is to develop the safety, feasibility, and tolerability of a personalized transcranial alternating current stimulation (tACS) approach in antenatal depression.
The purpose of this study is an initial pilot study to develop the safety, feasibility, and tolerability of a novel, individualized transcranial alternating current stimulation (tACS) approach in antenatal depression, which delivers personalized stimulation waveforms based on the aperiodic component of individual participant EEG activity (PandA-tACS). In Phase I, five healthy controls will receive five consecutive days of PandA-tACS. High-density electroencephalography will be collected at Baseline, D1 and D5, as well as intermittently throughout stimulation sessions. Symptoms will be checked at Follow-up 1 (FUP1) (two weeks following intervention). In Phase II, PandA-tACS will be expanded into five patients with antenatal depression with the same study design. In addition to high density (HD) HD-EEG measurements, depression and related symptoms will be measured at D1, D5 in these patients. Depression and related symptoms will be measured again FUP1 (two weeks following intervention) and Follow-up 2 (FUP2) (4-6 weeks post delivery). Birth outcomes will be recorded within 90 days of expected delivery date as an additional form of safety monitoring.
Primary Aim: To investigate the safety, feasibility, and tolerability of five days of PandA-tACS in healthy controls (Phase I) and in participants with antenatal depression (Phase II).
Exploratory Aim: To investigate aperiodic EEG changes following five days of PandA-tACS in healthy controls and in participants with antenatal depression. Additionally, changes in depression symptoms will be investigated two weeks following PandA-tACS in antenatal depression.
3,041 studies on the registry are indexed under Depressive Disorder, Major; 588 are open to participants now.
This study's enrollment of 6 is below the median of 79 across 2,530 interventional studies indexed under Depressive Disorder, Major.
Browse Depressive Disorder, Major studies →University of North Carolina, Chapel Hill is the lead sponsor of 1,372 studies on the registry; 133 are open to participants now.
Of its 161 completed or terminated interventional studies of FDA-regulated products, 139 (86%) have results posted.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Sep 28, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
For healthy control population:
Additional for antenatal depression population:
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
Additional for the healthy control population:
Additional for the antenatal depression population:
History of any of the following conditions:
Current pregnancy:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Aperiodic tACS delivered using a waveform based on individual participant EEG activity which has been modified to alter excitation/inhibition balance.
Device: tACS (aperiodic)
Aperiodic tACS delivered using a waveform based on individual participant EEG activity which has been modified to alter excitation/inhibition balance.
Device: tACS (aperiodic)
Individualized tACS waveform based on aperiodic EEG activity will be delivered.
Safety Via the Presence of Any Serious AEs Related to Stimulation
The number of serious adverse events reported in healthy control and antenatal depression groups.
Time frame: Healthy controls: Day 1 through Follow-up 1 (Day 19). Antenatal depression participants: Day 1 through birth outcome assessment within 90 days after delivery, up to 17 weeks after Day 1.
Feasibility Via the Number of Participants Enrolled Relative to the Target Recruitment in Each Group
The number of participants enrolled relative to the target recruitment of five participants in each of the healthy control and antenatal depression groups over the specified 12-month period
Time frame: Baseline to end of recruitment period (12 months following recruitment start)
Feasibility Via the Number of Participants Completing All Study Visits Within the Intervention Period
The number of participants who complete all study visits within the intervention period in the healthy control and antenatal depression groups.
Time frame: Baseline (up to 7 days before intervention Day 1) to Day 5 (end of five-day intervention)
Tolerability Via the Number of Participants Rating Stimulation-related Sensations as 'High'
The number of participants who rate stimulation-related sensations as 'high' within the intervention period in the healthy control and antenatal depression groups.
Time frame: Day 1 to Day 5
Tolerability Via the Proportion of Participants Reporting Intolerance to Stimulation
The proportion of participants who are unable to tolerate stimulation within the intervention period in the healthy control and antenatal depression groups.
Time frame: Day 1 to Day 5
Safety Via Review of Birth Outcomes Within 90 Days of Birth in the Antenatal Depression Population
The number of adverse birth outcomes in participants with antenatal depression. Review will consider length of pregnancy in days, delivery (spontaneous, induced, cesarian (planned or acute), vaginal birth, forceps and/or vacuum extraction), gestational age at birth, Apgar 5 min, malformation, child weight at birth in grams, birth size (small for gestational age, appropriate for gestational age, large for gestational age), neonatal need for intensive care, stillbirth, maternal length of stay in hospital, maternal need for intensive care, pre-eclampsia, as well as EPDS score between 2-4 weeks post-delivery .
Time frame: Healthy controls: Day 1 through Follow-up 1 (Day 19). Antenatal depression participants: Day 1 through birth outcome assessment within 90 days after delivery, up to 17 weeks after Day 1.
Change in Aperiodic Exponent Following the Five-day PandA-tACS Intervention
The change in aperiodic exponent from resting state EEG recordings on the first day and the final day of stimulation in healthy control and antenatal depression populations.
Time frame: Day 1 to Day 5
Change in HDRS-17 Score Following Intervention in the Antenatal Depression Population
The HDRS-17 is a clinician-administered depression assessment and consists of 17 items with a total score range from 0 to 52. A higher score indicates a worse outcome. Investigators will determine the change in scores across the intervention from Day 1 to Day 5, Day 1 to Follow-up 1, Day 5 to Follow-up 1
Time frame: Day 1 up to Follow-up 1 (2 weeks post-stimulation)
Change in Edinburgh Postnatal Depression Scale (EPDS) in the Antenatal Depression Population
The EPDS is a self-administered questionnaire designed to screen for potential symptoms of depression during pregnancy and the postpartum period. This scale consists of 10 short statements, where the participant checks off one of four possible answers about how they have been feeling for the past week. Responses are scored from 0-3, where total scores above 12 or 13 are likely to be suffering from depression. Investigators will determine the change in scores between across the intervention from Day 1 to Day 5, Day 1 to Follow-up 1, Day 5 to Follow-up 1.
Time frame: Day 1 up to Follow-up 1 (2 weeks post-stimulation)
Change in Snaith-Hamilton Pleasure Scale (SHAPS) in the Antenatal Depression Population
The SHAPS is a 14-item scale which assesses for anhedonia (the inability to experience pleasure) where each item has a set of four response categories (definitely agree=1, agree=2, disagree=3, definitely disagree=4). Participants are considered to be experiencing mild anhedonia if they disagree with three or more statements. Participants can agree or disagree on a minimum of 0 and maximum of 14 statements. Investigators will determine the change in scores across the intervention from Day 1 to Day 5, Day 1 to Follow-up 1, Day 5 to Follow-up 1.
Time frame: Day 1 up to Follow-up 1 (2 weeks post-stimulation)
Change in Clinical Global Impression Scale (CGI) in the Antenatal Depression Population
The CGI is a measure of symptom severity, treatment response and the efficacy of treatments. The CGI involves a single question for the clinician, who rates how mentally ill the participant is, on a scale from 1 (normal), 2 (borderline mentally ill), 3 (mildly ill), 4 (moderately ill), 5 (markedly ill), 6 (severely ill) and 7 (among the most extremely ill participants). Investigators will determine the change in scores across the intervention from Day 1 to Day 5, Day 1 to Follow-up 1, Day 5 to Follow-up 1.
Time frame: Day 1 up to Follow-up 1 (2 weeks post-stimulation)
Change in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-SF) in the Antenatal Depression Population
The Q-LES-Q-SF is a self-report measure of enjoyment and satisfaction in daily functioning. The total score ranges from 14 to 70, and is expressed as a percentage of the maximum total score that is achievable, where a percentage score ranging from 70-100 is generally indicative of a normal population. Investigators will determine the change in scores across the intervention by comparing scores from Day 1 to Day 5, Day 1 to Follow-up 1, Day 5 to Follow-up 1.
Time frame: Day 1 up to Follow-up 1 (2 weeks post-stimulation)
Change in HDRS-17 Score Following Intervention in the Antenatal Depression Population (Postnatal Period)
The HDRS-17 is a clinician-administered depression assessment and consists of 17 items with a total score range from 0 to 52. A higher score indicates a worse outcome. Investigators will determine the change in scores across the intervention from Follow-up 1 (2 weeks post-stimulation) to Follow-up 2 (4-6 weeks post delivery)
Time frame: Follow-up 1 (2 weeks post-stimulation) to Follow-up 2 (4-6 weeks post delivery)
Change in Edinburgh Postnatal Depression Scale (EPDS) in the Antenatal Depression Population (Postnatal Period)
The EPDS is a self-administered questionnaire designed to screen for potential symptoms of depression during pregnancy and the postpartum period. This scale consists of 10 short statements, where the participant checks off one of four possible answers about how they have been feeling for the past week. Responses are scored from 0-3, where total scores above 12 or 13 are likely to be suffering from depression. Investigators will determine the change in scores between Follow-up 1 (2 weeks post-stimulation) to Follow-up 2 (4-6 weeks post delivery)
Time frame: Follow-up 1 (2 weeks post-stimulation) to Follow-up 2 (4-6 weeks post delivery)
Change in Snaith-Hamilton Pleasure Scale (SHAPS) in the Antenatal Depression Population (Postnatal Period)
The SHAPS is a 14-item scale which assesses for anhedonia (the inability to experience pleasure) where each item has a set of four response categories (definitely agree=1, agree=2, disagree=3, definitely disagree=4). Participants are considered to be experiencing mild anhedonia if they disagree with three or more statements. Participants can agree or disagree on a minimum of 0 and maximum of 14 statements. Investigators will determine the change in scores across the intervention from Follow-up 1 (2 weeks post-stimulation) to Follow-up 2 (4-6 weeks post delivery)
Time frame: Follow-up 1 (2 weeks post-stimulation) to Follow-up 2 (4-6 weeks post delivery)
Change in Clinical Global Impression Scale (CGI) in the Antenatal Depression Population (Postnatal Period)
The CGI is a measure of symptom severity, treatment response and the efficacy of treatments. The CGI involves a single question for the clinician, who rates how mentally ill the participant is, on a scale from 1 (normal), 2 (borderline mentally ill), 3 (mildly ill), 4 (moderately ill), 5 (markedly ill), 6 (severely ill) and 7 (among the most extremely ill participants). Investigators will determine the change in scores across the intervention from Follow-up 1 (2 weeks post-stimulation) to Follow-up 2 (4-6 weeks post delivery)
Time frame: Follow-up 1 (2 weeks post-stimulation) to Follow-up 2 (4-6 weeks post delivery)
Change in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-SF) in the Antenatal Depression Population (Postnatal Period)
The Q-LES-Q-SF is a self-report measure of enjoyment and satisfaction in daily functioning. The total score ranges from 14 to 70, and is expressed as a percentage of the maximum total score that is achievable, where a percentage score ranging from 70-100 is generally indicative of a normal population. Investigators will determine the change in scores across the intervention by comparing scores from Follow-up 1 (2 weeks post-stimulation) to Follow-up 2 (4-6 weeks post delivery)
Time frame: Follow-up 1 (2 weeks post-stimulation) to Follow-up 2 (4-6 weeks post delivery)
| Milestone | Healthy Control Group | Antenatal Depression Group |
|---|---|---|
| Started | 5 | 0 |
| Completed | 5 | 0 |
| Not completed | 0 | 0 |
| Milestone | Healthy Control Group | Antenatal Depression Group |
|---|---|---|
| Started | 0 | 1 |
| Completed | 0 | 1 |
| Not completed | 0 | 0 |
The number of serious adverse events reported in healthy control and antenatal depression groups.
| Serious adverse events | Healthy Control Group | Antenatal Depression Group |
|---|---|---|
| Safety Via the Presence of Any Serious AEs Related to Stimulation | 0 | 0 |
The number of participants enrolled relative to the target recruitment of five participants in each of the healthy control and antenatal depression groups over the specified 12-month period
| percent of participants | Healthy Control Group | Antenatal Depression Group |
|---|---|---|
| Feasibility Via the Number of Participants Enrolled Relative to the Target Recruitment in Each Group | 100 | 20 |
The number of participants who complete all study visits within the intervention period in the healthy control and antenatal depression groups.
| Participants | Healthy Control Group | Antenatal Depression Group |
|---|---|---|
| Feasibility Via the Number of Participants Completing All Study Visits Within the Intervention Period | 5 | 1 |
The number of participants who rate stimulation-related sensations as 'high' within the intervention period in the healthy control and antenatal depression groups.
| Participants | Healthy Control Group | Antenatal Depression Group |
|---|---|---|
| Tolerability Via the Number of Participants Rating Stimulation-related Sensations as 'High' | 3 | 1 |
The proportion of participants who are unable to tolerate stimulation within the intervention period in the healthy control and antenatal depression groups.
| proportion of participants | Healthy Control Group | Antenatal Depression Group |
|---|---|---|
| Tolerability Via the Proportion of Participants Reporting Intolerance to Stimulation | 0 | 0 |
The number of adverse birth outcomes in participants with antenatal depression. Review will consider length of pregnancy in days, delivery (spontaneous, induced, cesarian (planned or acute), vaginal birth, forceps and/or vacuum extraction), gestational age at birth, Apgar 5 min, malformation, child weight at birth in grams, birth size (small for gestational age, appropriate for gestational age, large for gestational age), neonatal need for intensive care, stillbirth, maternal length of stay in hospital, maternal need for intensive care, pre-eclampsia, as well as EPDS score between 2-4 weeks post-delivery .
| Adverse events | Healthy Control Group | Antenatal Depression Group |
|---|---|---|
| Safety Via Review of Birth Outcomes Within 90 Days of Birth in the Antenatal Depression Population | — | 0 |
The change in aperiodic exponent from resting state EEG recordings on the first day and the final day of stimulation in healthy control and antenatal depression populations.
Results for this outcome have not been posted.
The HDRS-17 is a clinician-administered depression assessment and consists of 17 items with a total score range from 0 to 52. A higher score indicates a worse outcome. Investigators will determine the change in scores across the intervention from Day 1 to Day 5, Day 1 to Follow-up 1, Day 5 to Follow-up 1
Results for this outcome have not been posted.
The EPDS is a self-administered questionnaire designed to screen for potential symptoms of depression during pregnancy and the postpartum period. This scale consists of 10 short statements, where the participant checks off one of four possible answers about how they have been feeling for the past week. Responses are scored from 0-3, where total scores above 12 or 13 are likely to be suffering from depression. Investigators will determine the change in scores between across the intervention from Day 1 to Day 5, Day 1 to Follow-up 1, Day 5 to Follow-up 1.
Results for this outcome have not been posted.
The SHAPS is a 14-item scale which assesses for anhedonia (the inability to experience pleasure) where each item has a set of four response categories (definitely agree=1, agree=2, disagree=3, definitely disagree=4). Participants are considered to be experiencing mild anhedonia if they disagree with three or more statements. Participants can agree or disagree on a minimum of 0 and maximum of 14 statements. Investigators will determine the change in scores across the intervention from Day 1 to Day 5, Day 1 to Follow-up 1, Day 5 to Follow-up 1.
Results for this outcome have not been posted.
The CGI is a measure of symptom severity, treatment response and the efficacy of treatments. The CGI involves a single question for the clinician, who rates how mentally ill the participant is, on a scale from 1 (normal), 2 (borderline mentally ill), 3 (mildly ill), 4 (moderately ill), 5 (markedly ill), 6 (severely ill) and 7 (among the most extremely ill participants). Investigators will determine the change in scores across the intervention from Day 1 to Day 5, Day 1 to Follow-up 1, Day 5 to Follow-up 1.
Results for this outcome have not been posted.
The Q-LES-Q-SF is a self-report measure of enjoyment and satisfaction in daily functioning. The total score ranges from 14 to 70, and is expressed as a percentage of the maximum total score that is achievable, where a percentage score ranging from 70-100 is generally indicative of a normal population. Investigators will determine the change in scores across the intervention by comparing scores from Day 1 to Day 5, Day 1 to Follow-up 1, Day 5 to Follow-up 1.
Results for this outcome have not been posted.
The HDRS-17 is a clinician-administered depression assessment and consists of 17 items with a total score range from 0 to 52. A higher score indicates a worse outcome. Investigators will determine the change in scores across the intervention from Follow-up 1 (2 weeks post-stimulation) to Follow-up 2 (4-6 weeks post delivery)
Results for this outcome have not been posted.
The EPDS is a self-administered questionnaire designed to screen for potential symptoms of depression during pregnancy and the postpartum period. This scale consists of 10 short statements, where the participant checks off one of four possible answers about how they have been feeling for the past week. Responses are scored from 0-3, where total scores above 12 or 13 are likely to be suffering from depression. Investigators will determine the change in scores between Follow-up 1 (2 weeks post-stimulation) to Follow-up 2 (4-6 weeks post delivery)
Results for this outcome have not been posted.
The SHAPS is a 14-item scale which assesses for anhedonia (the inability to experience pleasure) where each item has a set of four response categories (definitely agree=1, agree=2, disagree=3, definitely disagree=4). Participants are considered to be experiencing mild anhedonia if they disagree with three or more statements. Participants can agree or disagree on a minimum of 0 and maximum of 14 statements. Investigators will determine the change in scores across the intervention from Follow-up 1 (2 weeks post-stimulation) to Follow-up 2 (4-6 weeks post delivery)
Results for this outcome have not been posted.
The CGI is a measure of symptom severity, treatment response and the efficacy of treatments. The CGI involves a single question for the clinician, who rates how mentally ill the participant is, on a scale from 1 (normal), 2 (borderline mentally ill), 3 (mildly ill), 4 (moderately ill), 5 (markedly ill), 6 (severely ill) and 7 (among the most extremely ill participants). Investigators will determine the change in scores across the intervention from Follow-up 1 (2 weeks post-stimulation) to Follow-up 2 (4-6 weeks post delivery)
Results for this outcome have not been posted.
The Q-LES-Q-SF is a self-report measure of enjoyment and satisfaction in daily functioning. The total score ranges from 14 to 70, and is expressed as a percentage of the maximum total score that is achievable, where a percentage score ranging from 70-100 is generally indicative of a normal population. Investigators will determine the change in scores across the intervention by comparing scores from Follow-up 1 (2 weeks post-stimulation) to Follow-up 2 (4-6 weeks post delivery)
Results for this outcome have not been posted.
Collected over All adverse events that occurred any time after informed consent was obtained until 7 days for Other (not including serious) adverse events or 30 days for Serious Adverse Events and unanticipated adverse device events after the last day of study participation (for healthy control group: 14 weeks after informed consent was obtained; for antenatal depression group: up to 19 weeks after informed consent was obtained).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Healthy Control Group | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| Antenatal Depression Group | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | Healthy Control Group | Antenatal Depression Group |
|---|---|---|
| "High" rated Tingling sensation during stimulationNervous system disorders | 0/5 | 1/1 |
| Age, Continuous(years) | Healthy Control Group | Antenatal Depression Group | Total |
|---|---|---|---|
| Mean | 34.0 ± 7.9 | 28.0 ± NA | 33.0 ± 7.5 |
| Sex: Female, Male(Participants) | Healthy Control Group | Antenatal Depression Group | Total |
|---|---|---|---|
| Female | 5 | 1 | 6 |
| Male | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Healthy Control Group | Antenatal Depression Group | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 3 | 1 | 4 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Healthy Control Group | Antenatal Depression Group | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 5 | 1 | 6 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Healthy Control Group | Antenatal Depression Group | Total |
|---|---|---|---|
| United States | 5 | 1 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Individual participant data will not be shared in this study due to the small sample size, which may cause participants to become identifiable.
Due to lack of resources the study was terminated.
Due to lack of resources the study was terminated.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of North Carolina, Chapel Hill →